A Study of Lisocabtagene Maraleucel (Liso-cel) for Transplant-Ineligible PCNSL
Phase 2
65
about 3.1 years
18+
30 sites in CA, CO, FL +10
About this study
Researchers are testing the safety and effectiveness of a treatment called lisocabtagene maraleucel (liso-cel) in adults with transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL). The trial will last about 1130 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Liso-cel
- 2.Take Calcium folinate
- 3.Take Cyclophosphamide
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
calcium folinate, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine, methotrexate, procarbazine, rituximab (Monoclonal antibody; targets CD20 on B-cells to destroy them), temozolomide
infusion, oral (Oral Tablet), oral (Oral Capsule), injection, intravenous
Primary: Progression-free Survival (PFS)
Secondary: Complete Response Rate (CRR), Duration of Response (DoR), Event-free Survival (EFS), Health-related quality of life (HRQoL), Modified Progression-free Survival (mPFS), Overall Response Rate (ORR), Overall Survival (OS), PFS
Oncology